文献速递外周动脉疾病

CHA2DS2-VASc评分用于症状性外周动脉疾病患者血管内治疗后风险分层

CHA2DS2-VASc Score for Risk Stratification After Endovascular Therapy in Patients With Symptomatic Peripheral Artery Disease.
PubMed 文献 · J Endovasc Ther · 2026-09-15

这项多中心回顾性研究纳入1584例2018至2020年因症状性外周动脉疾病接受血管内治疗的患者,按CHA2DS2-VASc评分分为低、中、高分组,评估其与3年全因死亡率的关联。结果显示3年全因死亡率随评分升高而递增(4.4%、17.2%、25.3%,log-rank P < .001),校正PAD特异性因素后评分仍独立相关(每增加1分HR 1.31,95%CI 1.21-1.43,P < .001)。

要点

  • CHA2DS2-VASc评分越高,EVT后3年全因死亡率呈阶梯式上升。
  • 校正PAD特异性因素后,评分每增加1分死亡风险独立增加31%。
  • 该关联在非房颤患者及间歇性跛行和慢性肢体威胁性缺血亚组中均可见。

核心结论

  • 在因症状性PAD接受EVT的患者中,较高的CHA2DS2-VASc评分与3年全因死亡率增加独立相关。

研究设计与样本

  • 多中心回顾性研究,纳入1584例2018至2020年因症状性PAD接受EVT的患者。
  • 按CHA2DS2-VASc评分分为低、中、高分组,主要终点为3年全因死亡率。
  • 采用Kaplan-Meier分析和多变量Cox比例风险模型评估评分与死亡率的关联。
  • 按房颤状态及PAD严重程度(间歇性跛行和慢性肢体威胁性缺血)进行亚组分析。

主要发现

  • 3年全因死亡率在低、中、高分组分别为4.4%、17.2%、25.3%(log-rank P < .001)。
  • 校正PAD特异性临床因素后,CHA2DS2-VASc评分每增加1分,全因死亡风险比为1.31(95%CI 1.21-1.43,P < .001)。
  • 该关联在非房颤患者中明显,并在间歇性跛行和慢性肢体威胁性缺血亚组中均观察到。

临床怎么用

  • CHA2DS2-VASc评分简单、通用且无需疾病特异性评估,可作为EVT后初步风险分层的辅助工具。
  • 该评分可补充已有的PAD特异性预后评估,用于常规临床实践中的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Risk stratification after endovascular therapy (EVT) for symptomatic peripheral artery disease (PAD) remains clinically important, particularly in patients with multiple comorbidities. The CHA2DS2-VASc score is a simple clinical score that incorporates major cardiovascular risk factors, but its prognostic utility after EVT for PAD has not been well established. This study evaluated the association between the CHA2DS2-VASc score and 3-year mortality in patients undergoing EVT for symptomatic PAD. METHODS: This multicenter retrospective study included 1584 patients who underwent EVT for symptomatic PAD between 2018 and 2020. Patients were classified into low, intermediate, and high CHA2DS2-VASc score groups. The primary outcome was all-cause mortality at 3 years. Kaplan-Meier analysis and multivariable Cox proportional hazards models were used to assess the association between the score and mortality. Subgroup analyses were additionally performed according to atrial fibrillation (AF) status and PAD severity, including intermittent claudication (IC) and chronic limb-threatening ischemia (CLTI). RESULTS: The rates of 3-year all-cause mortality increased stepwise across the low, intermediate, and high-score groups (4.4%, 17.2%, and 25.3%, respectively; log-rank P < .001). After adjustment for PAD-specific clinical factors, the CHA2DS2-VASc score remained independently associated with all-cause mortality (hazard ratio per 1-point increase, 1.31; 95% CI, 1.21-1.43; P < .001). This association was evident in patients without AF and was also observed in both IC and CLTI subgroups. CONCLUSIONS: In patients undergoing EVT for symptomatic PAD, a higher CHA2DS2-VASc score was independently associated with increased 3-year mortality. This widely available score may serve as a simple adjunctive tool for initial risk stratification after EVT and may complement established PAD-specific prognostic assessments.Clinical ImpactPatients undergoing endovascular therapy (EVT) for symptomatic peripheral artery disease remain at substantial risk of long-term mortality. In this multicenter study, the CHA₂DS₂-VASc score was independently associated with 3-year mortality across a broad spectrum of symptomatic PAD, including intermittent claudication and chronic limb-threatening ischemia. Although PAD- and CLTI-specific prognostic models provide superior discrimination, the CHA₂DS₂-VASc score is simple, universally recognized, and immediately available without disease-specific assessments. It may serve as an adjunctive tool for initial risk stratification and complement established prognostic models in routine clinical practice.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Shima Y, Karashima E, Kurimoto S, et al. CHA2DS2-VASc Score for Risk Stratification After Endovascular Therapy in Patients With Symptomatic Peripheral Artery Disease. J Endovasc Ther. 2026. PMID: 42740638. doi:10.1177/15266028261484801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。